---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046055"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T03:53:43.208938+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics reports FY2024 net loss $41.8M, cash $30.3M; amezalpat gets FDA designations

## Summary
- Net loss $41.8M ($1.50/share) vs $29.5M ($1.91/share) in 2023; R&D spend rose to $28.5M.
- Cash and equivalents $30.3M at Dec 31, 2024, down from $39.2M; ATM proceeds of $28.6M partially offset burn.
- Amezalpat (TPST-1120) received FDA Orphan Drug and Fast Track status for first-line HCC.
- Agreement signed with Roche to support pivotal Phase 3 trial of amezalpat + atezolizumab + bevacizumab in HCC.
- FDA cleared Phase 2 trial of TPST-1495 for familial adenomatous polyposis; data expected in 2026.

## SEC filing metadata
- accession: 0000950170-25-046055
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/0000950170-25-046055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017025046055/tpst-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046055
- JSON: https://secwatch.observer/filing/0000950170-25-046055.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.